Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alkem LaboratoriesNSE:ALKEM -1.50%97 EV-to-EBITDA is 18.20 as of Aug. 15, 2026, which is 9% below its 10-year median of 19.97. GuruFocus rates NSE:ALKEM with a GF Score™ of 97/100 and a GF Value™ of ₹6,140.73 (Modestly Undervalued). Among 735 Drug Manufacturers companies, Alkem Laboratories ranks worse than 63.81% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alkem Laboratories's enterprise value is ₹626,933 Mil.
Alkem Laboratories's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹34,441 Mil. Therefore, Alkem Laboratories's EV-to-EBITDA for today is 18.20.
The historical rank and industry rank for Alkem Laboratories's EV-to-EBITDA or its related term are showing as below:
NSE:ALKEM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 14.54 Med: 19.97 Max: 28.77
Current: 18.2
During the past 13 years, the highest EV-to-EBITDA of Alkem Laboratories was 28.77. The lowest was 14.54. And the median was 19.97.
NSE:ALKEM's EV-to-EBITDA is ranked worse than 63.81% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.3
vs NSE:ALKEM: 18.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alkem Laboratories's PE Ratio (TTM) for today is calculated as:
Alkem Laboratories's share price for today is ₹5368.00.
Alkem Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹180.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Alkem Laboratories's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkem Laboratories EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alkem Laboratories's EV-to-EBITDA falls into.
Alkem Laboratories's current Enterprise Value is ₹626,933 Mil.
Alkem Laboratories's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹34,441 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkem Laboratories (NSE:ALKEM) has a EV-to-EBITDA of 18.20 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alkem Laboratories. This is near median its historical median of 19.97. Over the past decade, Alkem Laboratories' EV-to-EBITDA has ranged from 14.54 to 28.77. According to the industry distribution chart, Alkem Laboratories ranks #469 out of 735 companies in the Drug Manufacturers industry, placing it in the top 63.8%.
Is Alkem Laboratories' EV-to-EBITDA too high?
Alkem Laboratories' current EV-to-EBITDA of 18.20 is near median its 10-year median of 19.97. Over the past 10 years, this metric has ranged from a low of 14.54 to a high of 28.77. The Drug Manufacturers industry median EV-to-EBITDA is 13.30. Alkem Laboratories' value of 18.20 is 36.8% above this industry median. Based on the distribution chart, Alkem Laboratories ranks #469 out of 735 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alkem Laboratories has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkem Laboratories' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alkem Laboratories ranks #469 out of 735 companies for EV-to-EBITDA. This places Alkem Laboratories in the lower half of its industry. The industry median EV-to-EBITDA is 13.30. Alkem Laboratories' value of 18.20 is 36.8% above this benchmark. Historically, Alkem Laboratories' own EV-to-EBITDA has ranged from 14.54 to 28.77 over the past decade. While the company's 10-year median is 19.97 vs. the industry median of 13.30, Alkem Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.30, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkem Laboratories's current EV-to-EBITDA of 18.20 is 36.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alkem Laboratories. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkem Laboratories's current EV-to-EBITDA is 18.20, which is near median its own 10-year median of 19.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alkem Laboratories (NSE:ALKEM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹6,140.73, compared to a current price of ₹5,368.00 — trading 12.6% below its estimated fair value. The current EV-to-EBITDA is 18.20, which is near median its 10-year median of 19.97 and 36.8% above the Drug Manufacturers industry median of 13.30. Alkem Laboratories' overall GF Score™ is 97/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alkem Laboratories (NSE:ALKEM), the current EV-to-EBITDA is 18.20 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkem Laboratories (NSE:ALKEM) Overvalued in 2026?
Based on GuruFocus' analysis, Alkem Laboratories stock appears to be undervalued.
The current stock price of ₹5,368.00 is trading 12.6% below its estimated GF Value™ of ₹6,140.73.
GuruFocus considers Alkem Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:ALKEM:
EV-to-EBITDA: 18.20 (near median its 10-year median of 19.97)
GF Value™: ₹6,140.73 vs. price of ₹5,368.00 (12.6% below fair value)
Industry Position: 36.8% above the Drug Manufacturers median (#469 of 735)
No single metric tells the full story. See the NSE:ALKEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
97GF Score
Get the complete analysis for NSE:ALKEM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALKEM has been successfully added to your 
